Reviewing Standard BioTools (NASDAQ:LAB) and Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health (NYSE:HIMS) and Standard BioTools (NASDAQ:LAB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Volatility and Risk

Hims & Hers Health has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 13.7% of Hims & Hers Health shares are owned by company insiders. Comparatively, 23.2% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Hims & Hers Health and Standard BioTools, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1	13	3	0	2.12
Standard BioTools	1	2	0	0	1.67

Hims & Hers Health presently has a consensus price target of $31.71, indicating a potential upside of 56.29%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 51.69%. Given Hims & Hers Health’s stronger consensus rating and higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than Standard BioTools.

Valuation and Earnings

This table compares Hims & Hers Health and Standard BioTools”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35 billion	1.97	$128.37 million	$0.51	39.79
Standard BioTools	$85.33 million	4.07	-$74.90 million	($0.20)	-4.45

Hims & Hers Health has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hims & Hers Health and Standard BioTools’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	5.47%	22.48%	7.02%
Standard BioTools	-59.39%	-11.21%	-8.51%

Summary

Hims & Hers Health beats Standard BioTools on 12 of the 14 factors compared between the two stocks.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.